Note: Descriptions are shown in the official language in which they were submitted.
CA 02588732 2009-12-10
1
EXTERNAL PATCHES CONTAINING ETOFENAMATE
TECHNICAL FIELD
The present invention relates to an external patch in which an
adhesive layer containing an adhesive base and a drug are laminated
with a backing.
BACKGROUND ART
Etofenamate, a non-steroidal anti-inflammatoric analgesic, is
used as a therapeutic agent for pain caused by stiff shoulders and
muscle weariness, contusion, distortion and so on in the form of ointments
and gels. However, in this regard to the ointments and the gels, control
of the amount to be administered is difficult, and as a volatile alcohol is
mixed in the preparations, skin-irritation and peculiar smell thereby
have been problematic. Furthermore, when using the preparations,
there is also the concern that hands or clothes are apt to be soiled.
To make up for. such disadvantages of the preparations, there is a
report on patches in which a synthetic rubber is used. For example, in
Japanese patent publication A 63-246327, are described patches which
contain etofenamate as a drug, styrene-isoprene-styrene block
copolymer (SIS block copolymer), an adhesive resin, liquid paraffin,
liquid gum and an antioxidant. However there is room to improve the
CA 02588732 2011-10-17
2
dermal permeability of etofenamate and skin-irritation in the patches.
DISCLOSURE OF INVENTION
The object of the present invention is to provide an external patch
which is excellent in skin-permeability of etofenamate, has excellent
anti-inflammatory activity and that is very low in skin-irritation.
BRIEF DESCRIPTION OF DRAWINGS
Figure 1 shows the amounts of cumulatively permeated
etofenamate in various patches.
SUMMARY OF THE INVENTION
The present inventors have earnestly studied in order to
resolve the above disadvantages, and as a result, have found that the
patches to meet the object can be prepared by adding etofenamate to
the adhesive base containing 5-50 % by weight of a synthetic rubber,
10-60 % by weight of an adhesive resin and 25-60 % by weight of liquid
paraffin.
Namely the present invention relates to an external patch in
which an adhesive layer containing an adhesive base and a drug is
laminated with a backing, wherein the adhesive base contains 5-50%
by weight of styrene-isoprene-styrene block copolymer, 10-60% by
weight of an alicyclic saturated hydrocarbon resin and 25-60% by
weight of liquid paraffin, 0.5-20% by weight of crotamiton and
isopropyl myristate as a plasticizer, and the drug is etofenamate.
CA 02588732 2009-12-10
3
MODE FOR CARRYING OUT THE INVENTION
The synthetic rubber used in dermally absorbable patches of the
present invention includes styrene-isoprene-styrene block copolymer
(SIS block copolymer), polyisobutylene, isoprene rubber, styrene-
butadiene-styrene block copolymer, silicon rubber, etc. The synthetic
rubber may be used in combination with them, but SIS block
copolymer is most preferred in consideration of skin-permeability of
the drug and physical property of the preparation.
The amount of the synthetic rubber is usually 5-50 % by weight,
preferably 5-40 % by weight, and more preferably 10-25 % by weight.
When less than 5 % by weight, the base is not aggregated and there is
a possibility that a part of the adhesive agent will remain on the skin
when the preparation is released from the skin. When over 50 % by
weight, the aggregation power becomes too strong and a decrease in
adhesivity occurs. Therefore, it becomes difficult to carry out the
spreading step of the base due to the high viscosity of the adhesive
agent in preparing the preparation.
The adhesive resin is usually to provide the patch adhesivity to
skin, and rosin resin and its derivative (rosin, rosin ester, hydrogenated
rosin, hydrogenated rosin esters), petroleum resin (alicyclic
hydrocarbon resin, aliphatic hydrocarbon resin), terpene resin, etc, are
used as the adhesive resin. In the present invention, preferably
petroleum resin, especially preferably, alicyclic saturated hydrocarbon
are used from the viewpoint of dermal absorbability and skin-adhesivity.
The amount of the adhesive resin is 10-60 % by weight, preferably
CA 02588732 2009-12-10
4
15-50 % by weight, and more preferably 20-40 % by weight. When
less than 10 % by weight, the adhesivity of the patch decreases
significantly. When beyond 60 % by weight, the adhesivity becomes
too strong and therefore, when releasing the patch from the skin,
physical stimulation occurs and the viscosity of the adhesive agent
becomes too high.
The liquid paraffin has the property to make soft the adhesive
agent and to improve the stickiness to skin in application and as well,
to control the adhesivity to skin and to reduce the physical irritation to
skin.
The amount of the liquid paraffin has a very important role in the
preparations of the present invention.
The amount of the liquid paraffin is 25-60 % by weight, preferably
25-50 % by weight, and more preferably 30-40 % by weight. When
less than 25 % by weight, the adhesivity becomes too strong, and
when releasing the patch from the skin, physical irritation occurs.
Furthermore, skin- permeability of the drug reduces significantly (see
Fig. 1). When beyond 60 % by weight, sufficient adhesivity is not
attained and the aggregation power of the adhesive agent reduces.
Therefore, there is a possibility that a part of the adhesive agent
remains on the skin.
It was also found that in the preparation of the present invention,
by further adding a plasticizer to the adhesive base, skin-permeability of
the drug can be enhanced.
The plasticizer used in the present invention includes triacetin,
CA 02588732 2009-12-10
crotamiton, fatty acid esters such as diethyl sebacate, triethyl citrate,
isopropyl myristate, etc., N-methylpyrollidone, etc.
The amount of the plasticizer is usually 0.5-20 % by weight,
preferably 1-10 % by weight, and more preferably 3-7 % by weight. The
5 plasticizer may be used in a combination of them. A combination of
crotamiton and isopropyl myristate is especially preferable as the
plasticizer used in the present invention.
The amount of crotamiton is preferably 0.5-5 % by weight. When
less than 0.5 % by weight, the effect of it is lessened. When beyond
5 % by weight, destruction of the aggregation of the adhesive agent
occurs and a part of the adhesive agent remains on the skin when
releasing the patch from the skin. The amount of isopropyl
myristate is preferably 0.5-15 % by weight. When less than 0.5 % by
weight, the effect of it is lessened. When beyond 15 % by weight, the
destruction of the aggregation of adhesive agent occurs and a part of
the adhesive agent remains on skin when releasing it from skin. The
ratio of crotamiton and isopropyl myristate is preferably 1:1-1:3 when
used in combination.
The amount of etofenamate used in the present invention is
usually 1-10 % by weight, preferably 2-8 % by weight, and more
preferably 3-6 % by weight. When less than 1 % by weight, the
amount of the drug released is lessened, there is a high possibility not
to attain the desired therapeutic effect, and when beyond 10 % by
weight, it becomes difficult to prepare the preparation in relation to the
other ingredients.
CA 02588732 2009-12-10
6
The patches of the present invention may contain, if necessary,
other ingredients, which are usually used in such patches, such as
antioxidants, fillers, preservatives, softeners, etc.
The antioxidant includes dibutyl hydroxytoluene, its derivative,
tocopherol, its derivative, ascorbic acid, its derivative, etc. The filler
includes calcium carbonate, magnesium carbonate, magnesium sulfate,
zinc oxide, titanium oxide, silicic acid and its salt (silicon dioxide,
aluminum silicate, magnesium silicate, light silicic anhydride, etc.), etc.
The preservative includes parabens (p-hydoxybenzoates), etc. The
softener includes petroleum oils (paraffin oil, aromatic oil, etc.), silicon
oil, liquid rubbers (polybutene, liquid isoprene rubber, etc.), high
molecular weight fatty acids, high molecular weight fatty acid esters,
polyhydric alcohols (polyethylene glycol, propylene glycol, diethylene
glycol, cyclopropylene glycol, glycerin, glycol salicylate, etc.), vegetable
oils (olive oil, eucalyptus oil), etc.
The thickness of the adhesive layer of the patches of the present
invention is not limited and is preferably 20-500 pm, and more
preferably 70-300 pm as when too thin the adhesivity reduces and
when too thick, the patches are readily released by rubbing with
clothes.
The backing to be used in the present invention is preferably
rich in flexibility, and includes, many kinds of woven textile,
unwoven textile, a vinyl chloride film, a polyethylene film, a
polyurethane film, etc. or a complexed film laminated these films.
The release liner to be used in the present invention includes
CA 02588732 2009-12-10
7
films, such as polyethylene terephthalate (PET), polypropylene,
polyethylene chloride, etc., and these films may be, if necessary treated
by silicon to give them suitable releasability.
The patches of the present invention are prepared as follows.
Namely a synthetic rubber, an adhesive resin, liquid paraffin, a
softener, an antioxidant, a filler, etc. were dissolved under heating.
After cooling, etofenamate, and if necessary a plasticizer, are added
thereto and the mixture is kneaded under stirring. The thus obtained
base is spread on a silicon-treated PET film, laminated with a backing
(polyester textile) and cut to a desired size to prepare the dermally
absorbable patches of the present invention.
The present invention is more concretely explained by the
following examples, but the present invention is not limited by them.
The term "part" in the examples means "part by weight", if it is
not defined otherwise.
According to the method mentioned above, dermally absorbable
patches having ingredients shown in Example 1 to Example 5 were
prepared.
A preparation (patch) containing ingredients of Example 5 except
liquid paraffin (5 parts) instead of etofenamate (5.0 parts) was also
prepared as a control preparation.
CA 02588732 2007-05-29
WO 2006/064576 PCT/JP2004/019143
8
Example -1
Etofenamate 5.0 (parts)
SIS block copolymer 15.0
Hydrogenated rosin glycerin ester 30.0
Liquid paraffin 38.0
Polybutene 10.0
Dibutyl hydroxytoluene 1.0
Light silicic anhydride 1.0
Total 100.0
Example 2
Etofenamate 5.0 (parts)
SIS block copolymer 15.0
Alicyclic saturated hydrocarbon 30.0
Liquid paraffin 38.0
Polybutene 10.0
Dibutyl hydroxytoluene 1.0
Light silicic anhydride 1.0
Total 100.0
Example 3
Etofenamate 5.0 (parts)
SIS block copolymer 15.0
Alicyclic saturated hydrocarbon 30.0
Liquid paraffin 33.0
Polybutene 10.0
Isopropyl myristate 5.0
Dibutyl hydroxytoluene 1.0
Light silicic anhydride 1.0
Total 100.0
CA 02588732 2009-12-10
9
Example 4
Etofenamate 5.0 (parts)
SIS block copolymer 15.0
Alicyclic saturated hydrocarbon 30.0
Liquid paraffin 36.0
Polybutene 10.0
Crotamiton 2.0
Dibutyl hydroxytoluene 1.0
Light silicic anhydride 1.0
Total 100.0
Example 5
Etofenamate 5.0 (parts)
SIS block copolymer 15.0
Alicyclic saturated hydrocarbon 30.0
Liquid paraffin 31.0
Polybutene 10.0
Isopropyl myristate 5.0
Crotamiton 2.0
Dibutyl hydroxytoluene 1.0
Light silicic anhydride 1.0
Total 100.0
A mixture of SIS block copolymer, hydrogenated terpene resin,
liquid paraffin, polybutene and an anti-oxidant was stirred under
heating. After cooling, etofenamate was added thereto and the mixture
was kneaded under stirring. The thus obtained based was spread on a
silicon-treated PET film, laminated with a backing (polyester textile) and
cut to a desired size to prepare a patch containing ingredients of the
Comparative example 1.
CA 02588732 2009-12-10
Comparative example 1 *
Etofenamate 10.0 (parts)
SIS block copolymer 30.0
Hydrogenated terpene resin 45.0
Liquid paraffin 4.5
Polybutene 10.0
Anti-oxidant 0.5
Total 100.0
Example 2 of Japanese patent publication A 63-24632
Etofenamate was added to acrylic polymer and thereto was added
5 a suitable amount of ethyl acetate in order to control the viscosity on
spreading to prepare an acrylic adhesive liquid. The acrylic adhesive
liquid was spread on a PET film, and the solvent was removed on drying
to prepare an adhesive layer. The layer was laminated with a backing
prepared by laminating a PET unwoven textile and a PET film to prepare
10 a patch containing ingredients of Comparative example 2.
Comparative example 2
Etofenamate 5.0 (parts)
Acrylic adhesive agent 95.0
Total 100.0
Etofenamate and isopropyl myristate were added to acrylic
polymer, and the mixture was prepared in accordance with the method of
Comparative example 2 to prepare a patch containing ingredients of
Comparative example 3.
CA 02588732 2009-12-10
11
Comparative example 3
Etofenamate 5.0 (parts)
Acrylic adhesive agent 90.0
Isopropyl myristate 5.0
Total 100.0
Etofenamate and crotamiton were added to acrylic polymer, and
the mixture was prepared in accordance with the method of Comparative
example 2 to prepare a patch containing ingredients of Comparative
example 4.
Comparative example 4
Etofenamate 5.0 (parts)
Acrylic adhesive agent 93.0
Crotamiton 2.0
Total 100.0
Etofenamate, isopropyl myristate and crotamiton were added to
acrylic polymer, and the mixture was prepared in accordance with the
method of Comparative example 2 to prepare a patch containing
ingredients of Comparative example 5.
Comparative example 5
Etofenamate 5.0 (parts)
Acrylic adhesive agent 88.0
Isopropyl myristate 5.0
Crotamiton 2.0
Total 100.0
CA 02588732 2009-12-10
12
Test 1: Skin-permeability test in vitro
In order to investigate skin-permeability of etofenamate, skin-
permeability test in vitro (rat) was carried out using the preparations
of Examples 1, 2, 3, 4 and 5 and Comparative examples 1, 2, 3, 4 and 5.
After removal of hair from the abdomen of rats, the skin of the abdomen
was taken out and fixed in a Frantz diffusion cell. In the inner part of
the cell, phosphate buffered physiological saline was filled as a receptor
solution. Water of 37 C was cyclized in a jacket over the cell. Each
patch was punched in a circle having diameter 2.5 cm and each circle
was applied on the skin on the cell. The sampling from the receptor
solution was carried out from time to time and the amount of
etofenamate permeated through the skin was measured by liquid
chromatography.
The result was shown in Figure 1. According to the result, the
preparation containing synthetic rubber was superior to the preparation
containing acrylic adhesive agent in skin-permeability of etofenamate.
In addition by making synthetic rubber contain the amount in more
than 25 % of liquid paraffin, skin-permeability of etofenamate was
raised, and by adding crotamiton and isopropyl myristate thereto, skin-
permeability was further raised.
Test 2: Inhibition test on edema induced on plantar of limb by
carrageenin
Each patch of Examples 2 to 5, Comparative examples 1 and 2
was cut in a size of 3 cm x 4 cm and the cut patch was applied on a
plantar of a right hind limb of a rat on 4 hours before administration of
CA 02588732 2009-12-10
13
carrageenin. One percent Carrageenin physiological saline (0.1 mL) was
subcutaneously administered to the plantar of the right hind limb of the
rat in order to induce edema on that region. Before administration and
4 hours later after administration, the volume of the limb was measured.
The inhibition rate of edema was calculated according to the
following calculation formula:
Formula :
Rate of edema (%) = {(volume of limb at 4 hours later after induction of
edema (mL) - volume of limb before induction of edema (mL))/volume of
limb before induction of edema (mL)} x 100
Inhibition rate (%) = {1 - rate of edema of test sample (%)/rate of
untreated control group (%)} x 100
The result was shown in Table- 1. All the preparations of the
present invention (Examples 2 to 5) showed inhibition of edema,
especially the preparation containing crotamiton and isopropyl
myristate showed a statistically significant difference compared with the
control preparation in the inhibition of edema (Student's t-test p < 0.01).
Table-1
Sample Rate of edema (%) Rate of inhibition (%)
Untreated 59.0 2.4 -
Control 58.9 3.7 0.17
Example 2 48.1 2.9 18.5
Example 3 42.0 3.8 28.8
Example 4 35.8 2.0 39.3
Example 5 26.5 1.7 55.1
Comparative example 1 52.4 4.5 11.2
Comparative example 2 54.6 3.3 7.46
CA 02588732 2009-12-10
14
Test 3: Adhesive test
In accordance with JIS Z0237 14: slant ball-tack method, each
preparation was measured on its adhesive power. Each patch of
Example 1, Example 2, Example 5, Comparative example 1,
Comparative example 2 and Comparative example 5 was cut in a size of
cm x 5 cm. The slant angle of the apparatus was set at 30 and
a slant plate made of acrylic polymer was used, and the length of the
run way and the measured part was 10 cm. The measurement was
three times per each preparation and the maximum number among the
10 number of balls which stayed for more than 5 minutes at the measured
part was counted.
The result was shown in Table-2. The preparation containing
synthetic rubber was superior to the preparation containing acrylic
adhesive agent in adhesive power, and the adhesive power of the
preparation containing further liquid paraffin (more than 25 %) was
improved.
Table-2
Sample Adhesive power
Example 1 22
Example 2 22
Example 5 24
Comparative example 1 18
Comparative example 2 16
Comparative example 5 16
Test 4: Primary skin-irritation test on rabbit
This test was carried out using Japanese white female rabbits (8
CA 02588732 2009-12-10
rabbits). After removal of hair from the back of a rabbit, each two patches
were applied to right and left sides, respectively. The right side was the
healthy part and the left side was the injured part. The injured part
was injured in the shape of # by a needle for injection. Each patch of
5 Control, Example 2, Example 5, Comparative example 1, Comparative
example 2 and Comparative example 5 (n=6) was punched in a circle of
a diameter having 2.5 cm and each of them was applied to the objected
regions. Each applied part was fixed by a tape (Band-aid, trade mark).
The rabbits were further covered with a protecting cloth to prevent
10 movement of the applied patches. Twenty four hours later after
application, each patch was removed, and the skin-reaction was
observed at 1 hour, 24 hours and 48 hours.
The judgement was conducted in accordance of the judgement
standard of Draize described in Table-3. Based on the judgement at 1
15 hour and 48 hours after removal of patches, the index of primary skin-
irritation (P. I. 1) was calculated.
The result was shown in Table-4. The preparations of the present
invention used in this test were lower in the irritation.
CA 02588732 2007-05-29
WO 2006/064576 PCT/JP2004/019143
16
Table-3: Standard of judgment of Draize
Item of observation and degree
No erythema ------------------------------------------------------------- 0
Slight erythema (barely distinctive) ---------------------------------- 1
Erythema
and scab Clear erythema -------------------------------------------------------
--- 2
Middle to strong erythema ---------------- ---------------------------- 3
Strong erythema with slight scab (deeply injured) ----------------- 4
No edema ----------------------------------------------------------------- 0
Slight edema (barely distinctive) -------------------------------------- 1
Edema Slight edema (outline of swelling being clear) ---------------------- 2
Middle ranked edema (swelling being to about 1mm height) ---- 3
Heavily ranked edema (swelling being to more than lmm height
and being enlarged to outside of region applied) ------------------ 4
Table-4
Average score of irritation
Sample State of skin reaction (n=6) P.I.I.
After 1 hour After 48 hours
Control Normal 0.3 0 0.3
Injured 0.7 0
Example 2 Normal 0.5 0 0.4
Injured 0.8 0.3
Example 5 Normal 0.2 0 0.2
Injured 0.5 0
Comparative Normal 1.2 0.7 1.0
example 1 Injured 1.3 1.0
Comparative Normal 1.5 0.5 1.3
example 2 Injured 2.0 0.5
Comparative Normal 1.3 1 1.2
example 5 Injured 1.3 0.7
It was confirmed by the above tests that the dermally absorbable
external patches containing etofenamate as an active ingredient of the
present invention have excellent skin-permeability and excellent
CA 02588732 2007-05-29
WO 2006/064576 PCT/JP2004/019143
17
therapeutic effect by etofenamate and as well, have a higher safety and
lower irritation.
